Michael Benkowitz sold $10.0M of UTHR
PRESIDENT AND COO at UNITED THERAPEUTICS Corp. 25,000 shares at an average of $398.85, traded Nov 6, 2024, filed Nov 8, 2024.
Score components
- +20RolePresident
- +25Trade size$10.0M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -9.8%, 3m -15.2%, 6m -26.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-026444, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 6, 2024 | MOption exercise Common Stockindirect: By Trust10b5-1 | +4,500 | $120.26 | $541k | 4,500 | Nov 8, 2024 |
| Nov 6, 2024 | MOption exercise Common Stockindirect: By Trust10b5-1 | +3,000 | $102.11 | $306k | 7,500 | Nov 8, 2024 |
| Nov 6, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -800 | $391.70 | $313k | 6,700 | Nov 8, 2024 |
| Nov 6, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -1,592 | $392.77 | $625k | 5,108 | Nov 8, 2024 |
| Nov 6, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -1,507 | $393.94 | $594k | 3,601 | Nov 8, 2024 |
| Nov 6, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -204 | $395.28 | $81k | 3,397 | Nov 8, 2024 |
| Nov 6, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -1,100 | $396.16 | $436k | 2,297 | Nov 8, 2024 |
| Nov 6, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -972 | $397.16 | $386k | 1,325 | Nov 8, 2024 |
| Nov 6, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -1,025 | $397.99 | $408k | 300 | Nov 8, 2024 |
| Nov 6, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -300 | $398.90 | $120k | 0 | Nov 8, 2024 |
| Nov 6, 2024 | MOption exercise Common Stockindirect: By Trust10b5-1 | +2,500 | $111.00 | $278k | 2,500 | Nov 8, 2024 |
| Nov 6, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -777 | $392.36 | $305k | 1,723 | Nov 8, 2024 |
| Nov 6, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -300 | $393.42 | $118k | 1,423 | Nov 8, 2024 |
| Nov 6, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -300 | $394.25 | $118k | 1,123 | Nov 8, 2024 |
| Nov 6, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -530 | $396.55 | $210k | 593 | Nov 8, 2024 |
| Nov 6, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -493 | $397.60 | $196k | 100 | Nov 8, 2024 |
| Nov 6, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -100 | $398.62 | $40k | 0 | Nov 8, 2024 |
| Nov 7, 2024 | MOption exercise Common Stockindirect: By Trust10b5-1 | +11,250 | $102.11 | $1.1M | 11,250 | Nov 8, 2024 |
| Nov 7, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -2,304 | $400.39 | $923k | 8,946 | Nov 8, 2024 |
| Nov 7, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -5,702 | $401.55 | $2.3M | 3,244 | Nov 8, 2024 |
| Nov 7, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -2,640 | $402.40 | $1.1M | 604 | Nov 8, 2024 |
| Nov 7, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -604 | $403.14 | $243k | 0 | Nov 8, 2024 |
| Nov 7, 2024 | MOption exercise Common Stockindirect: By Trust10b5-1 | +3,750 | $111.00 | $416k | 3,750 | Nov 8, 2024 |
| Nov 7, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -1,895 | $400.30 | $759k | 1,855 | Nov 8, 2024 |
| Nov 7, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -1,855 | $401.65 | $745k | 0 | Nov 8, 2024 |
| Nov 6, 2024 | MOption exercise Stock Optionsderivativeindirect: By Trust10b5-1 | -4,500 | $0.00 | $0 | 0 | Nov 8, 2024 |
| Nov 6, 2024 | MOption exercise Stock Optionsderivativeindirect: By Trust10b5-1 | -3,000 | $0.00 | $0 | 49,500 | Nov 8, 2024 |
| Nov 6, 2024 | MOption exercise Stock Optionsderivativeindirect: By Trust10b5-1 | -2,500 | $0.00 | $0 | 49,500 | Nov 8, 2024 |
| Nov 7, 2024 | MOption exercise Stock Optionsderivativeindirect: By Trust10b5-1 | -11,250 | $0.00 | $0 | 38,250 | Nov 8, 2024 |
| Nov 7, 2024 | MOption exercise Stock Optionsderivativeindirect: By Trust10b5-1 | -3,750 | $0.00 | $0 | 45,750 | Nov 8, 2024 |
Related signals
Other insiders at UNITED THERAPEUTICS Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.2M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.2M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.5M 9,500 shares | -3% | |
| 18Weak | UNITED THERAPEUTICS Corp | Paul A Mahon EVP & GENERAL COUNSEL | $4.7M 8,300 shares | -16% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $3.9M 7,580 shares | -2% | |
| 38Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $1.1M 1,920 shares | -1% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $4.5M 9,500 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.